Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

IIV-HD

Vaccine (Inactivated vaccine) · Immune activation · developed by Sanofi

Phase 3 Most advanced trial
SNY Developer
1 Registered trials

What is IIV-HD?

IIV-HD is an intramuscularly administered suspension studied for active immunization against influenza in healthy volunteers, with COVID-19 immunization also listed among the trial conditions.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine (Inactivated vaccine)
Mechanism
Immune activation
Therapy area
Infectious disease
Developer
Sanofi (SNY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07890454 Phase 3 Immunization Recruiting SNY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

COVID-19 ImmunizationHealthy VolunteersImmunizationInfluenza Immunization

More from Sanofi

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SNY page.

Follow SNY, the company behind IIV-HD

See SNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SNY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.